The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).
 
Frederic Pouliot
Stock and Other Ownership Interests - Allogene Therapeutics
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Novartis; Tersera; Tolmar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Tersera; Tolmar
Speakers' Bureau - Astellas Pharma; Bayer; Janssen
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Merck (Inst); Tersera (Inst)
Patents, Royalties, Other Intellectual Property - Transcriptional system and uses therof for single cell detection
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Étienne Rousseau
Employment - Alpha-9 Theranostics (I)
Stock and Other Ownership Interests - Alpha-9 Theranostics (I)
Patents, Royalties, Other Intellectual Property - Bénard F, Lin KS, Rousseau E, Zhang Z, Kwon D, Lau J, Uribe-Munoz C, Lozada J, Perrin D. Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy, US Patent US20220218852A1 (Published 2022-07-14), Priority to 62835733, Priority/invention da
 
Patrick O. Richard
Honoraria - Astellas Pharma; Bayer; Janssen Oncology; Knight Pharmaceuticals; Tolmar
Consulting or Advisory Role - Astellas Pharma; Bayer; Novartis
Travel, Accommodations, Expenses - Bayer
 
Atefeh Zamanian
No Relationships to Disclose
 
Stephan Probst
Honoraria - AAA/Endocyte/Novartis
Consulting or Advisory Role - AAA/Endocyte/Novartis
Research Funding - AAA/Endocyte/Novartis; POINT Biopharma
 
Eric Levesque
Honoraria - Bayer
 
Vincent Castonguay
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMS; Eisai; GlaxoSmithKline Canada; Ipsen; Janssen; Merck; Pfizer
Research Funding - AstraZeneca Canada (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Merck (Inst); Pfizer (Inst)
 
Nicolas Marcoux
Honoraria - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Merck; Pfizer; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Ipsen; Novartis; Pfizer; Seagen; Takeda
 
Daniel Juneau
Honoraria - AAA/Endocyte/Novartis
Consulting or Advisory Role - AAA/Endocyte/Novartis
 
Michele Lodde
No Relationships to Disclose
 
Jean-Baptiste Lattouf
Honoraria - Knight Therapeutics; Novartis; Tolmar
Consulting or Advisory Role - BMS GmbH & Co. KG; Knight Therapeutics; Novartis; Tolmar
Research Funding - AstraZeneca; BMS GmbH & Co. KG; Janssen
 
François-Alexandre Buteau
Honoraria - Lilly (I)
Consulting or Advisory Role - AAA/Endocyte/Novartis; Bayer
 
Zineb Hamilou
No Relationships to Disclose
 
Michel Pavic
Honoraria - Amgen; Astellas Pharma; EMD Serono; Janssen; Sanofi
Consulting or Advisory Role - Forus; Janssen; Merck; Novartis; Pfizer; Sanofi
 
Jean-François Castilloux
No Relationships to Disclose
 
Guillaume Bouvet
No Relationships to Disclose
 
Amélie Tetu
No Relationships to Disclose
 
Brigitte Guérin
Research Funding - AL-S Pharma AG (Inst); AL-S Pharma AG (Inst)
Patents, Royalties, Other Intellectual Property - PCT/CA2019/051777 License to Trasis
 
Jean-Mathieu Beauregard
Honoraria - Ipsen; Novartis
Consulting or Advisory Role - Novartis Canada Pharmaceuticals Inc
Research Funding - Ipsen (Inst); Novartis (Inst); Point Biopharma (Inst)